Enjoy complimentary customisation on priority with our Enterprise License!
Technavio’s market research analyst predicts the global osteoarthritis pain drugs market to grow at a CAGR of more than 8% by 2020. There are significant unmet medical needs in this market due to the chronic nature of osteoarthritis and the absence of effective curative therapies. The treatment options available in the market do not provide adequate pain relief in the late stages of osteoarthritis. This has led to a larger number of people opting for natural treatments such as yoga, chiropractic, homeopathy, and naturopathy to treat osteoarthritis. Several pharmaceutical companies are making investments to develop new drugs with better MOA and minimal adverse effects, which will propel the market’s growth during the forecast period.
According to this market analysis, an interesting trend gaining prominence in the market is the use of off-label drugs. Though these are unapproved medications, they provide effective treatment of osteoarthritis pain. Some of these off-label drugs include steroids and analgesics such as opioid or non-steroidal anti-inflammatory drugs (NSAIDs). People are opting for these drugs as they are less expensive than the approved drugs. Also, over-the-counter (OTC) pain medications such as aspirin, ibuprofen, naproxen sodium, morphine, fentanyl, and topical pain relievers such as creams, salves, or gels are used as maintenance therapies.
The oral ROA dominated the osteoarthritis pain drugs market in 2015 and accounted for around 66% of the overall market share. It is considered to be one of the safest and most preferred routes of drug administration. Oral administration ensures a systemic effect and the drugs administered through this route undergo the first-pass metabolism. The drugs that can be orally administered include tablets, capsules, and oral liquids. Some orally administered osteoarthritis drugs are tofacitinib, ibuprofen, naproxen, and acetaminophen.
APAC is expected to be the highest revenue contributing region in the osteoarthritis pain drugs market by 2020 owing to the fast growing populations in China, India, and Japan. Much of this region’s demand will be due to the growing need for better health management, better economic conditions, and awareness about the disease. Factors such as a rise in aging population and approval of drugs like MONOVISC and Vivlodex will drive the market in this region in the coming years.
The market is highly competitive with the presence of numerous small and large suppliers. The significant unmet needs of the market have led to the entry of several new players who have immense growth opportunities in the market. Vendors are forming strategic alliances to manufacture and promote their drugs and increase their market reach globally. Drugs with high safety and efficacy profile will dominate the market in the coming years.
Key vendors in the market are -
Other prominent vendors in the osteoarthritis pain drugs market are AbbVie, Abiogen Pharma, Afferent Pharmaceuticals, Astellas Pharma, BioDelivery Sciences International, CrystalGenomics, Cytori Therapeutics, Daiichi Sankyo, Eli Lilly, Endo Pharmaceuticals Holdings, Horizon Pharma, iCeutica, Iroko Pharmaceuticals, Merck, Nuvo Research, Regeneron Pharmaceuticals, Sanofi, SantoSolve, Techfields Pharma, Winston Pharmaceuticals, Yooyoung Pharmaceutical, and Zynerba Pharmaceuticals.
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Disease overview
PART 06: Pipeline portfolio
PART 07: Osteoarthritis pain drugs: Clinical trials
PART 08: Opportunities for research in osteoarthritis
PART 09: Market landscape
PART 10: Market segmentation by drug class
PART 11: Market segmentation by ROA
PART 12: Market segmentation by dosage form
PART 13: Geographical segmentation
PART 14: Market drivers
PART 15: Impact of drivers
PART 16: Market challenges
PART 17: Impact of drivers and challenges
PART 18: Market trends
PART 19: Vendor landscape
PART 20: Upcoming vendors with novel approaches
PART 21: Appendix
PART 22: Explore Technavio
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.